Agilent Technologies(NYSE) A

Agilent Technologies, Inc. makes tools for testing medicine and food. These products help scientists check the safety of everyday items. Labs and clinics use these systems for complex research.

Essential Tools for Global Science

• Agilent CrossLab: Laboratory services, consumables, and software for lab operations; generated $2,303 million in net revenue for the nine months ended July 31, 2026.
• Life Sciences and Diagnostics: Analytical instruments and clinical research tools for cellular and molecular testing; accounted for $2,157 million in net revenue for the nine months ended July 31, 2026.
• Applied Markets: Solutions for testing food, chemicals, and environmental samples; contributed $1,051 million in net revenue for the nine months ended July 31, 2026.

Strategic Acquisitions and Expansions

• Acquired Biocare on June 24, 2026, for $950 million to expand its pathology portfolio for clinical and research customers.
• Issued $600 million in senior notes on June 25, 2026, to manage its aggregate principal amount of debt.
• Invested in expanding advanced therapeutics manufacturing capacity in Frederick, Colorado, with planned capital expenditures of $450 million for fiscal year 2026.
• Completed a share repurchase program in Sept. 2025 and commenced a new $2.0 billion authorization to manage stock dilution.

Why Agilent Leads the Way

Agilent uses direct teams, distributors, and e-commerce platforms to reach customers in various scientific industries. The company integrates software, robotic systems, and analytical instruments to support entire laboratory workflows. These operational strengths allow the company to provide essential services across the global life sciences and diagnostics markets.

Financial Highlights by the Numbers

• Net revenue reached $5,511 million for the nine months ended July 31, 2026, up 8% year over year.
• Net income was $1,006 million for the nine-month period ended July 31, 2026, compared to $869 million for the same period last year.
• Cash provided by operations was $1,064 million during the nine months ended July 31, 2026.
• Total gross margin was 54.0% for the nine months ended July 31, 2026, up 2 percentage points year over year.
• The company paid $216 million in cash dividends during the nine months ended July 31, 2026.

Bottom Line

Agilent has transitioned from a measurement-focused business into a comprehensive provider of integrated laboratory solutions and clinical diagnostics. This evolution relies on combining analytical hardware with essential software and high-margin services to serve the global scientific community.